155
Participants
Start Date
October 31, 2025
Primary Completion Date
October 31, 2028
Study Completion Date
January 31, 2029
Govorestat
Govorestat will be provided as a liquid suspension (200mg/mL) for weight-based administration and administered orally at 20 mg/kg QD (every 24 hours)
Placebo Control
Placebo will also be provided as a matching liquid suspension to be taken orally QD
Sydney Childrens, Sydney
Charité - Universitätsmedizin Berlin, Berlin
CHU La Timone, Marseille
Clinic for Special Children, Gordonville
Carlo Besta Neurological Institute, Milan
Koç University Hospital, Istanbul
Istanbul University, Istanbul
University Medicine Gottingen (UMG), Göttingen
La Fe University and Polytechnic Hospital, Valencia
Uniklinik of the RWTH Aachen University, Aachen
University of Iowa, Iowa City
Institut de Myologie, Paris
Vall d'Hebron Institut de Recerca (VHIR), Barcelona
Lead Sponsor
Applied Therapeutics, Inc.
INDUSTRY